Identification of a serotonin/glutamate receptor complex implicated in psychosis
暂无分享,去创建一个
Graeme Milligan | Marta Filizola | Tony Yuen | Stuart C. Sealfon | Javier González-Maeso | Pokman Chan | S. Sealfon | T. Yuen | G. Milligan | Mingming Zhou | J. Gingrich | J. González-Maeso | N. Weisstaub | Pokman Chan | Rosalind L. Ang | M. Filizola | L. Callado | J. Meana | Jay A. Gingrich | Y. Okawa | Noelia V. Weisstaub | Mingming Zhou | Luis F. Callado | J. López-Giménez | J. Javier Meana | Juan F. López-Giménez | Yuuya Okawa | S. C. Sealfon | Noelia V. Weisstaub | Jay A. Gingrich | J. Meana
[1] Tony Yuen,et al. Method for multiplex cellular detection of mRNAs using quantum dot fluorescent in situ hybridization , 2005, Nucleic acids research.
[2] J. González-Maeso,et al. Quantitative stoichiometry of G-proteins activated by mu-opioid receptors in postmortem human brain. , 2002, European journal of pharmacology.
[3] Andreas Bäbler,et al. Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.
[4] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[5] J. Bockaert,et al. Extreme C Terminus of G Protein α-Subunits Contains a Site That Discriminates between Gi-coupled Metabotropic Glutamate Receptors* , 1998, The Journal of Biological Chemistry.
[6] S. Mosolov,et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.
[7] Andrea Iaboni,et al. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.
[8] Z. Xiang,et al. A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis , 2007, Molecular Pharmacology.
[9] Akira Sawa,et al. Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.
[10] N. Cairns,et al. Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. , 2003, Brain research. Molecular brain research.
[11] Huda Akil,et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. , 2004, Human molecular genetics.
[12] K. Heekeren,et al. Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers , 2005, Pharmacopsychiatry.
[13] Terry Kenakin,et al. Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.
[14] J. Lieberman,et al. Serotonergic basis of antipsychotic drug effects in schizophrenia , 1998, Biological Psychiatry.
[15] Graeme Milligan,et al. The α1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function , 2007, Molecular Pharmacology.
[16] F. Vollenweider,et al. Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia , 2003, Neuropsychopharmacology.
[17] Krzysztof Palczewski,et al. Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.
[18] F. Colpaert. Discovering risperidone: the LSD model of psychopathology , 2003, Nature Reviews Drug Discovery.
[19] H. Weinstein,et al. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. , 2003, Molecular Pharmacology.
[20] G. Marek. Metabotropic glutamate 2/3 receptors as drug targets. , 2004, Current opinion in pharmacology.
[21] K. Heekeren,et al. Inhibition of Return in the Human 5HT2A Agonist and NMDA Antagonist Model of Psychosis , 2006, Neuropsychopharmacology.
[22] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[23] E. Myers,et al. Basic local alignment search tool. , 1990, Journal of molecular biology.
[24] Manfred Burghammer,et al. Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.
[25] F. Vollenweider,et al. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.
[26] G. Aghajanian,et al. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. , 2000, The Journal of pharmacology and experimental therapeutics.
[27] P. Ornstein,et al. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. , 2001, The Journal of pharmacology and experimental therapeutics.
[28] Franz X Vollenweider,et al. A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.
[29] J. Lieberman,et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.
[30] Krzysztof Palczewski,et al. Rhodopsin dimers in native disc membranes: Neat rows of paired photon receptors are caught on camera in their natural state , 2003 .
[31] S. Sealfon,et al. Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.
[32] Michel Bouvier,et al. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.
[33] A. Carlsson. The Neurochemical Circuitry of Schizophrenia , 2006, Pharmacopsychiatry.
[34] J. John Mann,et al. Cortical 5-HT2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice , 2006, Science.
[35] G. Aghajanian,et al. Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.
[36] B. Dean. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice , 2003, Journal of neurochemistry.
[37] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[38] Stuart C. Sealfon,et al. Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.
[39] Bertil Hille. G protein-coupled receptor , 2009, Scholarpedia.
[40] J. Joyce,et al. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study , 1997, Biological Psychiatry.
[41] P. Ornstein,et al. [H]LY341495 Binding to Group II Metabotropic Glutamate Receptors in Rat Brain , 2001 .
[42] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[43] Gilles Labesse,et al. Common Structural Requirements for Heptahelical Domain Function in Class A and Class C G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.
[44] Philip D. Harvey,et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. , 1995, The American journal of psychiatry.